Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy.

Álvarez-Lerma F, Rodriguez M, Soriano MC, Catalán M, Llorente AM, Vidart N, Garitacelaya M, Maravi E, Fernández Rey E, Alvarado F, López-Sánchez M, Alvarez-Sánchez B, Granado D, Quintana E; Study Group of Liposomal Amphotericin B in the ICU.

Rev Esp Quimioter. 2013 Dec;26(4):360-8.

2.

Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.

Alvarez-Lerma F, Soriano MC, Rodríguez M, Catalán M, Llorente AM, Vidart N, Garitacelaya M, Maraví E, Fernández E, Alvarado F, López M, Alvarez-Sánchez B, Espinosa J, Quintana E; Study Group of Liposomal Amphotericin B in the ICU.

Rev Esp Quimioter. 2012 Sep;25(3):206-15.

3.

Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT).

Piccinni P, Cruz DN, Gramaticopolo S, Garzotto F, Dal Santo M, Aneloni G, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluomo Anello C, Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C; NEFROINT Investigators.

Minerva Anestesiol. 2011 Nov;77(11):1072-83. Epub 2011 May 11.

4.

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.

Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.

Pharmacoeconomics. 2004;22(5):301-10.

PMID:
15061680
5.

Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury.

Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators.

J Crit Care. 2009 Mar;24(1):129-40. doi: 10.1016/j.jcrc.2007.12.017. Epub 2008 Apr 18.

PMID:
19272549
6.

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.

Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-Regidor MA, Ibáñez-Lucía P, Torres-Rodríguez JM.

Intensive Care Med. 1997 Jan;23(1):23-30.

PMID:
9037636
7.
8.

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.

Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE.

Br J Haematol. 1997 Sep;98(3):711-8.

PMID:
9332329
9.
10.

Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury.

Elseviers MM, Lins RL, Van der Niepen P, Hoste E, Malbrain ML, Damas P, Devriendt J; SHARF investigators.

Crit Care. 2010;14(6):R221. doi: 10.1186/cc9355. Epub 2010 Dec 1.

11.

Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.

Azoulay E, Timsit JF, Lautrette A, Legriel S, Max A, Ruckly S, Misset B, Cohen Y, Wolff M.

PLoS One. 2017 May 22;12(5):e0177093. doi: 10.1371/journal.pone.0177093. eCollection 2017.

12.

Intermittent hemodialysis versus continuous renal replacement therapy for acute renal failure in the intensive care unit: an observational outcomes analysis.

Rauf AA, Long KH, Gajic O, Anderson SS, Swaminathan L, Albright RC.

J Intensive Care Med. 2008 May-Jun;23(3):195-203. doi: 10.1177/0885066608315743.

PMID:
18474503
13.

Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies.

Benoit DD, Hoste EA, Depuydt PO, Offner FC, Lameire NH, Vandewoude KH, Dhondt AW, Noens LA, Decruyenaere JM.

Nephrol Dial Transplant. 2005 Mar;20(3):552-8. Epub 2005 Jan 25.

PMID:
15671075
14.

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP.

Pharmacotherapy. 2007 Jul;27(7):970-9.

15.

RIFLE-based data collection/management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute kidney injury in the intensive care unit.

Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G, Kim JC, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluomo Anello C, Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C; NEFROINT investigation group.

Blood Purif. 2011;31(1-3):159-71. doi: 10.1159/000322161. Epub 2011 Jan 10.

16.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
17.
18.

Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study.

Alvarez-Lerma F, Mariscal F, Quintana E, Rialp G, Diaz-Reganon J, Perez MJ, Alvarez-Sanchez B, Ausin Aoiz I; Study Group of Liposomal Amphotericin B in the Icu.

J Chemother. 2009 Jun;21(3):330-7.

PMID:
19567355
19.

Estimating the impact of renal replacement therapy choice on outcome in severe acute renal failure.

Swartz RD, Bustami RT, Daley JM, Gillespie BW, Port FK.

Clin Nephrol. 2005 May;63(5):335-45.

PMID:
15909592
20.

Supplemental Content

Support Center